Nath Bio-Genes (India)'s Q3 FY 2025-26 Quarterly Results
- 01 Feb 2026
Result Summary
- Nath Bio-Genes (India) Ltd reported a 47.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 81.2%.
- Its expenses for the quarter were up by 60.1% QoQ and 102.3% YoY.
- The net profit decreased 41.8% QoQ and decreased 39.6% YoY.
- The earnings per share (EPS) of Nath Bio-Genes (India) Ltd stood at 0.84 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 67.69 | 45.78 | 37.35 | 47.9% | 81.2% |
Total Expenses | 67.90 | 42.40 | 33.56 | 60.1% | 102.3% |
Profit Before Tax | 2.48 | 5.46 | 3.79 | -54.6% | -34.6% |
Tax | 0.87 | 0.64 | 1.14 | 35.9% | -23.7% |
Profit After Tax | 1.60 | 2.75 | 2.65 | -41.8% | -39.6% |
Earnings Per Share | 0.84 | 1.40 | 1.33 | -40.0% | -36.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nath Bio-Genes (India) Ltd is a company engaged in the production and distribution of agricultural seeds. The company is part of the agribusiness industry, where it focuses on developing hybrid and genetically modified seeds for a variety of crops, including cotton, rice, and vegetables. This sector is crucial for enhancing agricultural productivity and ensuring food security. Currently, there is no specific information available on recent major developments for Nath Bio-Genes (India) Ltd within the provided data. However, the sector generally faces dynamic challenges and opportunities related to agricultural trends, climate change, and technological advancements.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Nath Bio-Genes (India) Ltd reported a total income of ₹67.69 crores, reflecting a significant quarter-over-quarter (QoQ) increase of 47.9% from ₹45.78 crores in Q2FY26. Comparatively, the year-over-year (YoY) growth was even more pronounced, with total income increasing by 81.2% from ₹37.35 crores in Q3FY25. These figures highlight substantial revenue growth over both periods, demonstrating the company's ability to expand its income base significantly within a fiscal year.
Profitability
The company's profitability metrics for Q3FY26 indicate notable changes. Profit Before Tax (PBT) decreased to ₹2.48 crores, marking a decline of 54.6% QoQ from ₹5.46 crores in Q2FY26, and a decrease of 34.6% YoY from ₹3.79 crores in Q3FY25. The Tax expense increased to ₹0.87 crores in Q3FY26, a 35.9% rise from ₹0.64 crores in the previous quarter, but decreased by 23.7% from ₹1.14 crores in the same quarter last year. Profit After Tax (PAT) stood at ₹1.60 crores, showing a decline of 41.8% QoQ from ₹2.75 crores, and a 39.6% decrease YoY from ₹2.65 crores. These metrics highlight variations in profitability despite increased revenue.
Operating Metrics
The financial data provided for Nath Bio-Genes (India) Ltd reveals several key operating metrics. Total expenses for Q3FY26 were ₹67.90 crores, which is a 60.1% increase QoQ from ₹42.40 crores in Q2FY26 and a 102.3% increase YoY from ₹33.56 crores in Q3FY25. The Earnings Per Share (EPS) for the third quarter was ₹0.84, down by 40.0% from ₹1.40 in the previous quarter and 36.8% from ₹1.33 in the same quarter of the previous year. These figures illustrate changes in cost structure and shareholder returns over the specified periods. The analysis of these operating metrics provides insights into the company's efficiency in managing its expenses relative to income growth.